SCHEMBL1709838

SCHEMBL1709838

FC(F)CNc1nc(Cl)nc2ccoc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 8/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
APP P05067 2/20 0.36
PDE5A O76074 1/20 0.36
JAK2 O60674 2/20 0.35
ABL1 P00519 2/20 0.35
LCK P06239 2/20 0.35
FYN P06241 2/20 0.35
RET P07949 2/20 0.35
MAPK8 P45983 2/20 0.35
TNK2 Q07912 2/20 0.35
MAP4K2 Q12851 2/20 0.35
NTRK2 Q16620 2/20 0.35
INSR P06213 1/20 0.35
MST1 P26927 1/20 0.35
TTK P33981 1/20 0.35
MAP4K4 O95819 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3711032 0.85 ESR1 (0.45) SYKPDE4APDE4BPDE4CPDE4D
SCHEMBL3708672 0.80 PDE4A (0.44) SYKPDE4APDE4BPDE4CPDE4D
SCHEMBL1709887 0.79 SYK (0.51) SYKPDE4APDE4BPDE4CPDE4D
SCHEMBL3701517 0.78 PDE4A (0.45) SYKPDE4APDE4BPDE4CPDE4D
SCHEMBL3712321 0.75 TLR7 (0.39) SYKPDE4APDE4BPDE4CPDE4D
SCHEMBL31690997 0.75 APP (0.67) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL22652133 0.75 PDE4A (0.39) SYKPDE4APDE4BPDE4CPDE4D
SCHEMBL3713429 0.74 XDH (0.37) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL31691093 0.74 PDE5A (0.50) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL3715489 0.74 SYK (0.41) SYKPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
WO-2012048222-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 SYK 1176/4885PDE4A 1055/4885PDE4B 1241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.